• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novaccess Global Inc (OP:XSNX)

0.0001 UNCHANGED
Streaming Delayed Price Updated: 1:55 PM EST, Jan 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 0.0001
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.0001
Today's Range 0.0001 - 0.0001
52wk Range 0.0001 - 0.0004
Shares Outstanding N/A
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
NovAccess Global Files Patent with Cedars-Sinai to Advance its Brain Cancer Fighting Vaccine Platform
May 21, 2024
Via ACCESSWIRE
News headline image
NovAccess Global Advisory on Annual Meeting of Shareholders
May 07, 2024
Via ACCESSWIRE

Performance

YTD
N/A
N/A
1 Month
N/A
N/A
3 Month
N/A
N/A
6 Month
-66.7%
-66.7%
1 Year
-50.0%
-50.0%

More News

Read More
News headline image
NovAccess Global Announces New License to Advance its Immunotherapy Platform
April 30, 2024
Via ACCESSWIRE
News headline image
NovAccess Global Announces $10.7 Million Financing
January 02, 2024
Via ACCESSWIRE
News headline image
NovAccess Global Appoints Dr. Roscoe M. Moore, Jr. to Scientific Advisory Board
November 10, 2023
Via ACCESSWIRE
News headline image
NovAccess Global Partners with BCN Biosciences to Expand Immunotherapy Platform
July 27, 2023
Via ACCESSWIRE
News headline image
NovAccess Global Lead Scientist Published in High-Profile Medical Journal for Cancer Vaccine Advancements
May 11, 2023
Via ACCESSWIRE
News headline image
Dr. Christopher Wheeler, NovAccess Lead Scientist, Receives Prestigious Golden Axon Award
March 15, 2023
Via ACCESSWIRE
News headline image
NovAccess Global to Participate in National Brain Tumor Society's Annual Glioblastoma Awareness Day
July 13, 2023
Via ACCESSWIRE
News headline image
NovAccess Global Partners with CKN Ventures to Expand its New AI-driven Precision Medicine Division
June 16, 2023
Via ACCESSWIRE
News headline image
NovAccess Global Launches Precision Medicine Division Using AI, Big Data and Predictive Technologies to Accelerate Personalized Healthcare Therapies
June 01, 2023
Via ACCESSWIRE
News headline image
NovAccess Global to Present at World Orphan Drug Congress
February 16, 2023
Via ACCESSWIRE
News headline image
NovAccess Global Leadership to Present at World Brain Mapping Foundation Annual Congress
February 03, 2023
Via ACCESSWIRE
News headline image
NovAccess Global Announces Fireside Chat with Dr. Christopher Wheeler, the Company’s Lead Scientist and President of its StemVax Therapeutics Division
January 05, 2023
Via ACCESSWIRE
News headline image
NovAccess Global Announces Initial Fireside Chat with Glioblastoma Patient Advocate
November 22, 2022
Via ACCESSWIRE
News headline image
NovAccess Global Announces Virtual Annual Shareholders' Meeting
November 08, 2022
Via ACCESSWIRE
News headline image
NovAccess Global Appoints Healthcare IP Consultant Dr. Peter Weinstein to Scientific Advisory Board
November 10, 2022
Via ACCESSWIRE
News headline image
NovAccess Global Receives FDA Approval of Orphan Drug Application for TLR-AD1
October 26, 2022
Via ACCESSWIRE
News headline image
NovAccess Global Announces Fireside Chat with Board Member Perspectives
October 20, 2022
Via ACCESSWIRE
News headline image
NovAccess Global Announces Fireside Chat Series for the Investment Community
September 29, 2022
Via ACCESSWIRE
News headline image
NovAccess Global Announces Effectiveness of Form S-1 Registration Statement
September 22, 2022
Via ACCESSWIRE
News headline image
NovAccess Global Announces Uplisting to OTCQB
August 10, 2022
Via ACCESSWIRE
News headline image
CORRECTION: NovAccess Global Announces Filing of Orphan Drug Application for TLR-AD1
July 19, 2022
Via ACCESSWIRE
News headline image
NovAccess Global Announces Filing of Orphan Drug Application for TLR-AD1
July 19, 2022
Via ACCESSWIRE
News headline image
CORRECTION: NovAccess Global Announces Filing of Orphan Drug Application for TLR-AD1
July 19, 2022
From NovAccess Global Inc.
Via AccessWire

Frequently Asked Questions

Is Novaccess Global Inc publicly traded?
Yes, Novaccess Global Inc is publicly traded.
What exchange does Novaccess Global Inc trade on?
Novaccess Global Inc trades on the OTC Traded
What is the ticker symbol for Novaccess Global Inc?
The ticker symbol for Novaccess Global Inc is XSNX on the OTC Traded
What is the current price of Novaccess Global Inc?
The current price of Novaccess Global Inc is 0.0001
When was Novaccess Global Inc last traded?
The last trade of Novaccess Global Inc was at 01/06/26 01:55 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap